（2025 年 8 月） 第一章 总则 第一条 为规范公司领导人员的产生，优化董事会组成，完善公司治理结构， 根据《中华人民共和国公司法》、《陕西盘龙药业集团股份有限公司章程》（以下 简称"公司章程"）等有关规定，公司设立董事会提名委员会，并制定本议事规 则。 陕西盘龙药业集团股份有限公司董事会提名委员会实施细则 陕西盘龙药业集团股份有限公司 董事会提名委员会实施细则 第二条 董事会提名委员会是董事会按照股东会决议设置的专门工作机构， 主要负责对公司董事、高级管理人员的人选、选择标准和程序进行选择并提出建 议，直接对董事会负责。 第二章 人员组成 第三条 提名委员会委员由三名董事组成，其中独立董事过半数并担任召集 人。 第四条 提名委员会委员由董事长、二分之一以上独立董事或全体董事的三 分之一提名，并由董事会选举产生。 第五条 提名委员会设主任委员一名，由独立董事担任，主任委员负责主持 委员会工作；主任委员在委员内选举，并报董事会备案。 第六条 提名委员会任期与董事会任期一致，委员任期届满连选可以连任。 期间如有委员不再任董事职务，自动失去委员资格，由委员会根据上述第三至第 五条规定补足委员人数。 第七条 提 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-035 陕西盘龙药业集团股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、召开会议的基本情况 1.股东会届次：2025 年第二次临时股东会； 2.股东会的召集人：陕西盘龙药业集团股份有限公司（以下简称"公司"）董事会； 3.会议召开的合法、合规性：经公司第四届董事会第二十五次会议审议通过，决定 召开公司 2025 年第二次临时股东会，本次会议的召开符合《中华人民共和国公司法》 《上市公司股东会规则》《深圳证券交易所股票上市规则》等有关法律法规及《公司章 程》的规定。 4.会议召开的日期、时间： （1）现场会议召开日期：2025 年 9 月 15 日（星期一）下午 14:00； （2）网络投票时间为：2025 年 9 月 15 日；其中，通过深圳证券交易所交易系统 进行网络投票的具体时间为：2025 年 9 月 15 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体 ...

陕西盘龙药业集团股份有限公司 第四届监事会第二十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002864 证券简称：盘龙药业 公告编号：2025-031 一、监事会会议召开情况 1．陕西盘龙药业集团股份有限公司（以下简称"公司"）第四届监事会第 二十一次会议通知于 2025 年 8 月 16 日以邮件和电话方式向各位监事发出。 2．本次会议于 2025 年 8 月 26 日 14:00 在西安市灞桥区现代纺织产业园灞 柳二路 2801 号陕西盘龙医药股份有限公司二楼会议室召开，本次会议采用现场 与通讯相结合方式召开。 3．应出席监事 5 人，实际出席监事 5 人。 4．公司监事会主席罗庆水先生主持了本次会议。 5．本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律、 行政法规、部门规章、规范性文件及《陕西盘龙药业集团股份有限公司章程》的 有关规定。 二、监事会会议审议情况 1.审议并通过了《关于<2025年半年度报告>及其摘要的议案》 表决结果：同意5票，反对0票，弃权0票。 经审核，监事会认为：董事会编制和审核公司《 ...

Meeting Information - The company will hold its second extraordinary general meeting of shareholders in 2025 on September 15, 2025, at 14:00 [1] - The network voting will take place on the same day, with specific time slots for voting through the Shenzhen Stock Exchange trading system [1] Eligibility to Attend - All ordinary shareholders registered by the close of trading on September 5, 2025, are eligible to attend the meeting and can appoint agents to represent them [2] - Company directors, supervisors, senior management, and appointed lawyers are also allowed to attend [2] Agenda Items - The meeting will review several proposals, including the election of independent directors, which require a two-thirds majority vote from attending shareholders [2][3] - Proposals will be counted separately for small and medium investors [3] Registration Process - Shareholders must provide identification and relevant documents to register for the meeting [3][4] - Remote shareholders can register via mail or fax, with a deadline of September 12, 2025 [4] Voting Procedures - Shareholders can participate in voting through the Shenzhen Stock Exchange trading system and the internet voting system [5] - Specific procedures for casting votes, including the allocation of votes for independent and non-independent director candidates, are outlined [5][6] Additional Information - The company will provide detailed instructions for network voting and necessary forms for proxy authorization and shareholder registration [5][7][8]

陕西盘龙药业集团股份有限公司股东会议事规则 陕西盘龙药业集团股份有限公司 （2025 年 月） 第一章 总则 相关法律、法规及规范性文件的规定，制定本规则。 第二条 公司应当严格按照法律、法规、公司章程及本规则的相关规定召开 股东会，保证股东能够依法行使权利。公司董事会应当切实履行职责，认真、按 时组织股东会。公司全体董事应当勤勉尽责，确保股东会正常召开和依法行使职 权。 公司应当完善股东会运作机制，平等对待全体股东，保障股东依法享有的知 情权、查询权、分配权、质询权、建议权、股东会召集权、提案权、提名权、表 决权等权利，积极为股东行使权利提供便利，切实保障股东特别是中小股东的合 法权益。公司应当积极采用累积投票、网络投票等方式，为股东特别是中小股东 参加股东会及行使表决权提供便利。具体规定详见《股东会网络投票管理制度》、 《累积投票制度实施细则》、《中小投资者单独计票机制实施细则》。 第一条 为维护陕西盘龙药业集团股份有限公司（以下简称"公司"）股东 合法权益，明确股东会的职责权限，保证股东会依法行使职权，根据《中华人民 共和国公司法》 （以下简称"公司法"）、 《中华人民共和国证券法》 第三条 股东会是公 ...

Core Viewpoint - The financial report of Shaanxi Panlong Pharmaceutical Group Co., Ltd. for the first half of 2025 shows significant growth in revenue and net profit compared to the same period in 2024, indicating a positive trend in the company's financial performance [5][7][8]. Financial Performance - Total operating revenue for the first half of 2025 reached CNY 574,023,000.14, an increase from CNY 455,356,633.75 in the same period of 2024, representing a growth of approximately 26.0% [5][7]. - The net profit for the first half of 2025 was CNY 59,979,473.51, slightly up from CNY 59,435,447.41 in the first half of 2024, indicating a stable profit margin [7][8]. - Basic and diluted earnings per share remained consistent at CNY 0.57 for the first half of 2025, unchanged from the previous year [8]. Assets and Liabilities - Total assets increased to CNY 2,362,246,494.51 at the end of the first half of 2025, compared to CNY 2,280,023,009.54 at the beginning of the year, reflecting a growth of approximately 3.6% [3][4]. - Total liabilities rose to CNY 696,000,341.43, up from CNY 642,840,255.08, indicating an increase of about 8.3% [4][5]. - The total equity attributable to shareholders increased to CNY 1,664,436,104.93 from CNY 1,635,217,029.35, showing a growth of approximately 1.8% [4][5]. Cash Flow - The net cash flow from operating activities for the first half of 2025 was CNY 62,620,899.02, down from CNY 111,157,587.41 in the same period of 2024, indicating a decrease in cash generation from operations [9][10]. - Cash and cash equivalents at the end of the first half of 2025 were CNY 1,166,765,970.54, slightly down from CNY 1,169,375,189.16 at the beginning of the year [9][10]. Cost Structure - Total operating costs for the first half of 2025 were CNY 502,134,108.31, compared to CNY 391,905,428.80 in the same period of 2024, reflecting an increase of approximately 28.2% [7][8]. - The cost of goods sold was CNY 280,795,329.78, up from CNY 171,037,480.65, indicating a significant rise in production costs [7][8].

Core Viewpoint - The announcement details the upcoming election of the fifth board of directors for Shanxi Panlong Pharmaceutical Group Co., Ltd., which will consist of 9 members, including 5 non-independent directors, 3 independent directors, and 1 employee representative director [1][3]. Board Election Details - The fifth board of directors will be composed of 9 members: 5 non-independent directors, 3 independent directors, and 1 employee representative director [1]. - The board's election will be conducted through a cumulative voting system for both non-independent and independent directors [3]. Candidate Nomination - The board's nomination committee has approved the following candidates for the fifth board: - Non-independent directors: Xie Xiaolin, Wu Jie, Xie Xiaofeng, Zhang Dezhuz, Huang Jilin - Independent directors: Niu Xiaofeng, Wang Mancang, Wang Peng [2]. Candidate Qualifications - All nominated candidates have been confirmed to meet the qualifications required for directors of a listed company, in accordance with relevant laws and regulations [2]. - The number of directors who are also senior management or employee representatives will not exceed half of the total board members, and independent directors will account for at least one-third of the board [2]. Term and Transition - The term for the new board of directors will be three years, starting from the date of approval at the company's second extraordinary general meeting in 2025 [3]. - Current board members will continue to fulfill their duties until the new board is officially in place [3]. Independent Director Tenure - Independent directors cannot serve more than six consecutive years, and two current independent directors are approaching the end of their terms [3].

| - 款 非经营性往来 | | | | 资金周转 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 北京实达信科技服务有限公司 | | | 全资孙公司 | | 其他应收款 | 610.00 | | | | 200.00 - | 810.00 | 资金周转 | 非经营性往来 | | | | | | | 过去十二个月内与公司存在关联关系的控 | | | | | | | | | | 陕西盘龙鸿业大药房有限公司 | | | | 应收账款 | 3.83 | | - | | | 0.12 3.71 销售货款 | | 经营性往来 | | | | | | | | 其他关联方及其附 | | | 股公司 | | | | | | | 属企业 过去十二个月内与公司存在关联关系的控 | | | | | | | | | | 陕西盘龙鸿业大药房有限公司 | | | | 其他应收款 | | | | | | 16.50 - | - | 16.50 | 资金周转 | 非经营性往来 | | | | | | 股公司 | | | | | | | | | | 总计 ...

Core Viewpoint - The financial report of Shaanxi Panlong Pharmaceutical Group Co., Ltd. for the first half of 2025 shows an increase in total assets and net profit compared to the same period in 2024, indicating a positive growth trend in the company's financial performance [2][5][6]. Financial Summary Assets - Total assets at the end of the first half of 2025 amounted to CNY 2,362,246,494.51, an increase from CNY 2,280,023,009.54 at the beginning of the year, reflecting a growth of approximately 3.6% [2][3]. - Current assets totaled CNY 1,855,373,268.19, up from CNY 1,771,523,291.39, marking an increase of about 4.7% [2][3]. - Non-current assets slightly decreased to CNY 506,873,226.32 from CNY 508,499,718.15, a decline of approximately 0.3% [2][3]. Liabilities - Total liabilities increased to CNY 696,000,341.43 from CNY 642,840,255.08, representing a rise of about 8.2% [3][4]. - Current liabilities rose to CNY 485,824,666.12, compared to CNY 446,110,297.49, an increase of approximately 8.9% [3][4]. - Non-current liabilities also increased to CNY 210,175,675.31 from CNY 196,729,957.59, reflecting a growth of about 6.8% [3][4]. Equity - Total equity reached CNY 1,666,246,153.08, up from CNY 1,637,182,754.46, indicating an increase of approximately 1.8% [3][4]. - Retained earnings increased to CNY 688,550,110.23 from CNY 659,732,692.20, a growth of about 4.4% [3][4]. Revenue and Profit - Operating revenue for the first half of 2025 was CNY 574,023,000.14, compared to CNY 455,356,633.75 in the same period of 2024, marking an increase of approximately 26% [5][6]. - Net profit for the first half of 2025 was CNY 59,979,473.51, slightly up from CNY 59,435,447.41 in 2024, indicating a marginal growth of about 0.9% [5][6]. - Basic and diluted earnings per share remained stable at CNY 0.57 [5][6]. Cash Flow - Net cash flow from operating activities was CNY 62,620,899.02, down from CNY 111,157,587.41 in the previous year, indicating a decrease of approximately 43.7% [7]. - Cash and cash equivalents at the end of the period were CNY 1,166,765,970.54, slightly down from CNY 1,164,710,997.88 [7].

Core Viewpoint - The company, Shanxi Panlong Pharmaceutical Group Co., Ltd., is revising its Articles of Association and related corporate governance systems to enhance governance efficiency and streamline management processes, including the abolition of the supervisory board and the transfer of its responsibilities to the audit committee of the board of directors [1][2][3]. Summary by Sections Revision of Articles of Association - The company plans to amend its Articles of Association to comply with the latest regulatory framework and improve governance effectiveness [1][2]. - The supervisory board will be dissolved, and its functions will be transferred to the audit committee, pending approval from the shareholders' meeting [1][2]. Specific Amendments - The amendments will include changes to the roles and responsibilities of the board of directors and the legal representative of the company [4][5]. - The new provisions will clarify that the legal representative's civil activities will be the company's responsibility, and the company can seek compensation from the legal representative if damages occur due to their duties [4][5]. Governance Structure Changes - The supervisory board's responsibilities will cease upon the approval of the revised Articles of Association, and the rules governing the supervisory board will be abolished [2][3]. - The company will ensure that the audit committee will diligently perform its supervisory functions until the shareholders' meeting approves the changes [2][3]. Legal Compliance - The revisions are in accordance with the Company Law, Securities Law, and relevant regulations from the Shenzhen Stock Exchange [3][4]. - The company emphasizes that the amendments aim to protect the rights and interests of shareholders, employees, and creditors while ensuring compliance with legal requirements [1][2].